HOME >> BIOLOGY >> NEWS
Wolf reintroduction reshapes Yellowstone ecology

The 1995 reintroduction of wolves in the northern range of Yellowstone National Park has led to increased growth of willow and cottonwood in the park by causing fear responses in elk and other ungulates, according to William J. Ripple and Robert L. Beschta of Oregon State University in Corvallis. Ripple and Beschta, writing in the August 2004 issue of BioScience, argue that fear of predation when wolves are present changes grazing patterns, prompting grazers to avoid sites that deny them easy escape and to browse less thoroughly. The "terrain fear factor" consequently allows woody plants and trees to grow taller and thicker when wolves are present. This in turn has allowed beaver colonies to expand.

Ripple and Beschta base their conclusions on theory about feeding relationships between species, browsers' risk of predation since the reintroduction of wolves into the park in 1995, and empirical research. In the view of Ripple and Beschta, extirpation of wolves in the early 20th century was "most likely the overriding cause of the precipitous decline and cessation in the recruitment of aspen, cottonwood and willow across the nothern range."

The new theory thus brings a significant new factor into long-running, intense debates over the proper management of Yellowstone. Ripple and Beschta conclude that, for Yellowstone, "restoration goals should focus on the recovery of natural processes." The identified fear factor might also be important in other regions, although the evidence is less well developed. Journalists may obtain copies of the article by contacting Donna Royston, AIBS communications representative.


'"/>

Contact: Donna Royston
droyston@aibs.org
202-628-1500 x261
American Institute of Biological Sciences
2-Aug-2004


Page: 1

Related biology news :

1. 19th century museum specimens help plan reintroduction of endangered tiger beetle
2. Yellowstones long-distance travelers in trouble, study says
3. Wolves are rebalancing Yellowstone ecosystem
4. Yellowstone wolves, grizzlies and moose dysfunctional study says
5. Lake tributaries in Yellowstone National Park allow unique study of whirling disease
6. Without bears and wolves to hunt them, Yellowstone moose have lost some spring in their step, study says
7. Scientist searches Yellowstone Park for carbon dioxide-eating microbe
8. New study shows bison dont favor groomed roads in Yellowstone National Park
9. Microbial transport at Yellowstone: by land, sea or air?
10. Wolves in Yellowstone may aid aspen recovery
11. USGS scientist receives award for brucellosis research in Greater Yellowstone Area

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Wolf reintroduction reshapes Yellowstone ecology

(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... The empty capsules market is ... population and technological innovations in the empty capsules ... catalysing the growth of the empty capsules market. ... , Scope of Report , The report will ... entrants/smaller firms to gauge the pulse of the ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: